<SEC-DOCUMENT>0001193125-23-196770.txt : 20230728
<SEC-HEADER>0001193125-23-196770.hdr.sgml : 20230728
<ACCEPTANCE-DATETIME>20230728063156
ACCESSION NUMBER:		0001193125-23-196770
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230728
FILED AS OF DATE:		20230728
DATE AS OF CHANGE:		20230728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		231120144

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d405104d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated July 28, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d405104dex991.htm">First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: July 28, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d405104dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g405104sp4.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX announcement </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>First Patient Dosed
in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 28</B><B></B><B>&nbsp;July
</B><B>2023 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer
and autoimmune disease, today announces the first patient has been enrolled and safely dosed in <FONT STYLE="white-space:nowrap">EFTISARC-NEO,</FONT> the Phase II investigator-initiated trial of eftilagimod alpha (efti), a soluble <FONT
STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist, in combination with radiotherapy and the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) for patients with soft tissue sarcoma. This chemo-free trial is the first to evaluate efti in a neoadjuvant setting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Soft tissue sarcoma (STS), an orphan disease, represents a high unmet medical need with a poor prognosis. The incidence of STS varies in different regions,
with approximately 23,400 cases annually and a crude incidence of 4.7 per 100,000 in Europe, according to the RARECARE project. In the United States, the number of new cases is estimated to be 13,400 annually with 5,140 deaths, according to the
American Cancer Society. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The open-label <FONT STYLE="white-space:nowrap">EFTISARC-NEO</FONT> Phase II study, which will treat up to 40 patients, is being
conducted by the Maria Sk&#322;odowska-Curie National Research Institute of Oncology (MSCNRIO) and is primarily funded with an approved grant from the Polish government awarded by the Polish Medical Research Agency program. The trial&#146;s
Principal Investigators are Dr.&nbsp;Katarzyna Kozak, M.D., Ph.D., and Pawe&#322; Sobczuk, M.D., Ph.D., medical oncologists at the Department of Soft Tissue/Bone Sarcoma and Melanoma at MSCNRIO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Pawe&#322; Sobczuk stated: &#147;Soft tissue sarcoma is a rare, aggressive disease in high need of new therapeutic approaches, and we are pleased to
begin treating patients with this novel <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IO-IO-radiotherapy</FONT></FONT> combination and look forward to evaluating the potential synergistic effects of this chemo-free therapy. In
particular, efti&#146;s sustained activation of antigen-presenting cells, leading to proliferation of activated CD8+ T cells and elevated interferon-gamma levels, may transform the immunosuppressed tumour microenvironment of soft tissue sarcomas
into one that enables immune checkpoint inhibitors like pembrolizumab to exert their anti-cancer effect. Additionally, we see synergies between efti and radiotherapy to arm, activate, and proliferate cytotoxic T cells with radiotherapy-induced
cancer antigens to target this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> tumour.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep
CSO, Fr&eacute;d&eacute;ric Triebel, M.D., Ph.D, said:<B> </B>&#147;We are pleased to see this trial, led by the expert team at the Maria Sk&#322;odowska-Curie National Research Institute, begin to enrol and dose patients. <FONT
STYLE="white-space:nowrap">EFTISARC-NEO</FONT> represents the first time efti will be evaluated in the neoadjuvant, <FONT STYLE="white-space:nowrap">non-metastatic</FONT> cancer setting where patients will receive efti much earlier on in their
cancer journey. Also, the neoadjuvant setting gives us the opportunity to assess in the surgical specimen the changes in the tumour microenvironment induced by efti. New information arising from this innovative trial may further broaden the future
clinical development of efti and, in the end, bring even greater benefit to patients.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> clinical stage candidate that is a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator that stimulates both innate and adaptive immunity for the treatment of cancer. Efti binds to MHC II molecules on APCs leading to activation/proliferation
of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>
and CXCL10 that further boost the immune system&#146;s ability to fight cancer. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g405104sp4.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug
Administration (FDA). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About The Maria Sk&#322;odowska-Curie National Research Institute of Oncology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Maria Sk&#322;odowska Curie National Research Institute of Oncology is the leading Polish comprehensive cancer centre, as well as the primary government
research institution devoted solely to oncology. Founded in 1932 by Maria Sklodowska-Curie, it is currently divided into 28 specialised clinical departments responsible for the diagnostics and therapy of different tumour types such as: Breast Cancer
Clinic, Head and Neck Cancer Clinic, General and Visceral Surgery, Thoracic Surgery, Urology, Gynaecology, Haematology, Soft Tissue/Bone Sarcoma and Melanoma Clinic, Radiation Oncology, Brachytherapy and Diagnostic Radiology, Pathology and Molecular
Medicine and Cell Research, Oncology, Gastroenterology, Cancer Epidemiology and Prevention Division and others. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune
disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio
harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information,
please visit <U>www.immutep.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>cstrong@citadelmagnus.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris
Basta, VP, Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g405104sp4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g405104sp4.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M\5\9T^F?\BQ!_P!>_P#2M8_"=E/^&CAO#O\ R,%G_O\ ]#7/#XCSZ'QH]'U
M9TRZ'_3)OY5U/8].>S."\)?\C#'_ +K?RK"'Q'G8?^(=UJHSI%Y_UQ?^1K9[
M,]"I\+.'\'?\AX?]<V_I6%+<X,-\8SXG?\?6G?[C_P Q72>D=)X$8-X3M0#D
MJ7!]OF- &)\3_P#4:;_O/_(4 7/AK_R+UQ_U\M_Z"M '$ZWQXTNO^OO_ -FH
M ]H% &%XS#GPE?B/.=JYQZ;AG]* /*]"L]3O+YHM*F:*XV$DK+Y9*Y&>?RH
MZ/\ X1WQO_S_ %Q_X&G_ !H ;IO@O7H-:M+NXC0A)UDD8R@G ;)/O0!;^)W^
MOTW_ '9/_9: .C\"_P#(HV?U?_T,T 1^/B@\)7.[&=Z;?KN'_P!>@#G_ (8!
MOM&HG^':F?KDT >CT % !0 4 4-:_P"0)??]<'_E2>S,ZOP,XSP7_P AM_\
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M""19(K.%)%Z,J $4**6Q/)%.Z1;9%="C %2,$'O3+*L.F65M()(+6*-QP&5
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: % !0 4 % !0 4 % !0 4 % !0 4 % '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
